Choose any of the summaries on the right to read an introduction to the disease and discover related resources.
Inflammatory condition of skin
This section encompasses a wide range of skin conditions, comprising a number of separate aetiologies. They fall into this category due to their common inflammatory pathology,...
Congestive heart failure
Congestive heart failure in simple terms is failure of the heart as a pump. Prevalence is rising, as it tends to affect people later in life and is also most commonly a result...
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
A number of presentations and abstracts shared updates on the latest developments for new treatments and therapies, some of which are pioneering new modes of action. Here we look to the horizon, gaining insights into the latest data for novel treatments targeting Janus kinase (JAK) signalling, MAdCAM-1-mediated adhesion and the interleukin IL-23.
While clinical trials have demonstrated the efficacy of new biologics used in ulcerative colitis and/or Crohn’s disease, it is apparent that patients enrolled into clinical trials are not representative of the general patient population. Real-world evidence offers the chance to fill this gap and provide insights into how these treatments perform in everyday clinical practice. In today’s article we review some of the real-world data shared at UEG Week on vedolizumab and ustekinumab, as well as comparison of the originator and biosimilar versions of infliximab.
The introduction of biologic therapies in the last 20 years has revolutionised the management of IBD. However, questions remain over the best approach to its management, such as when to introduce, switch and de-escalate biologics. Several posters and presentations addressed these topics at UEG Week 2018; here is a selection of some of the highlights.
In our final report from ESMO 2018 we share insights from the Proffered paper session - Gastrointestinal tumours, colorectal, moderated by Dirk Arnold (Hamburg, DE) and Alfredo Falcone (Pisa, IT). Here, we cover survival data from the MODUL trial, comparing maintenance fluorouracil-bevacizumab and fluorouracil-bevacizumab plus atezolizumab in BRAF wild-type disease, and [in TRIBE2] consider the impact on PFS2 of an intensified treatment strategy versus a standard, sequential treatment strategy.